Open Access Open Access  Restricted Access Subscription Access

Objectives, Symptoms, Mechanism of Action, Administration, Adverse Effects, Contraindications, Monitoring, Toxicity and Enhancing Health Care Team Outcomes of Lipid Lowering Agent Namely Bempedoic Acid

Muralinath E., Guruprasad M., Madhavi Latha C., Sheethal U., Vyshnavi J., Varsha V., Prathysha M.V.S., Karthik Jayanth Y.

Abstract


Bempedoic acid is a lipid-lowering drug that is crucial for treating individuals with high levels of low-density lipoprotein cholesterol (LDL-C). The U.S. Food and Drug Administration (FDA) has approved its use as a maximally effective supplement to tolerated statin medication for the reduction of LDL-C, particularly in people affected by heterozygous familial hypercholesterolemia (HeFH) and atherosclerotic cardiovascular disease (ASCVD). For those who are intolerant to statins, bempedoic acid is another good option. The drug's indications, mechanism of action, administration methods, major side effects, contraindications, and monitoring procedures are all covered in this program.

The course also covers monitoring methods, pharmacokinetic nuances, and associated cautions and warnings. Medical practitioners can effectively treat hyperlipidemia and guide patient management with this knowledge. A thorough understanding of the complex pharmacology of bempedoic acid allows physicians to tailor treatment plans to the needs of individual patients. This allows for the optimization of dosage schedules, the reduction of potential adverse reactions, and the making of informed prescription decisions. In order to treat patients with hypercholesterolemia and deliver evidence-based care, this activity equips medical professionals with the necessary tools.

 


Full Text:

PDF

References


Agarwala, A., & Goldberg, A. C. (2020). Bempedoic acid: A promising novel agent for LDL-C lowering. Future Cardiology, 16(5), 361–371. https://doi.org/10.2217/fca-2019-0085

Ballantyne, C. M., Davidson, M. H., MacDougall, D. E., Bays, H. E., DiCarlo, L. A., Rosenberg, N. L., Margulies, J., & Newton, R. S. (2013). Efficacy and safety of a novel dual modulator of adenosine triphosphate-citrate lyase and adenosine monophosphate-activated protein kinase in patients with hypercholesterolemia: Results of a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial. Journal of the American College of Cardiology, 62(13), 1154–1162. https://doi.org/10.1016/j.jacc.2013.05.050

Marrs, J. C., & Anderson, S. L. (2020). Bempedoic acid for the treatment of dyslipidemia. Drugs in Context, 9, 2020-5-5. https://doi.org/10.7573/dic.2020-5-5

Nissen, S. E., Lincoff, A. M., Brennan, D., Ray, K. K., Mason, D., Kastelein, J. J. P., Thompson, P. D., Libby, P., Cho, L., Plutzky, J., Bays, H. E., Moriarty, P. M., Menon, V., Grobbee, D. E., Louie, M. J., Chen, C. F., Li, N., Bloedon, L., Robinson, P., ... CLEAR Outcomes Investigators. (2023). Bempedoic acid and cardiovascular outcomes in statin-intolerant patients. The New England Journal of Medicine, 388(15), 1353–1364. https://doi.org/10.1056/NEJMoa2215024

Ruscica, M., Banach, M., Sahebkar, A., Corsini, A., & Sirtori, C. R. (2019). ETC-1002 (bempedoic acid) for the management of hyperlipidemia: From preclinical studies to phase 3 trials. Expert Opinion on Pharmacotherapy, 20(7), 791–803. https://doi.org/10.1080/14656566.2019.1583558

Biolo, G., Vinci, P., Mangogna, A., Landolfo, M., Schincariol, P., Fiotti, N., Mearelli, F., & Di Girolamo, F. G. (2022). Mechanism of action and therapeutic use of bempedoic acid in atherosclerosis and metabolic syndrome. Frontiers in Cardiovascular Medicine, 9, 1028355. https://doi.org/10.3389/fcvm.2022.1028355

Keaney, J. F. (2023). Bempedoic acid and the prevention of cardiovascular disease. The New England Journal of Medicine, 388(15), 1427–1430. https://doi.org/10.1056/NEJMe2302291

Ruscica, M., Sirtori, C. R., Carugo, S., Banach, M., & Corsini, A. (2022). Bempedoic acid: For whom and when. Current Atherosclerosis Reports, 24(10), 791–801. https://doi.org/10.1007/s11883-022-01037-7

Newman, C. B., Blaha, M. J., Boord, J. B., Cariou, B., Chait, A., Fein, H. G., Ginsberg, H. N., Goldberg, I. J., Murad, M. H., Subramanian, S., & Tannock, L. R. (2020). Lipid management in patients with endocrine disorders: An Endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism, 105(12), 3613–3682. https://doi.org/10.1210/clinem/dgaa674

Virani, S. S., Newby, L. K., Arnold, S. V., Bittner, V., Brewer, L. C., Demeter, S. H., Dixon, D. L., Fearon, W. F., Hess, B., Johnson, H. M., Kazi, D. S., Kolte, D., Kumbhani, D. J., LoFaso, J., Mahtta, D., Mark, D. B., Minissian, M., Navar, A. M., Patel, A. R., ... Williams, M. S. (2023). 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA guideline for the management of patients with chronic coronary disease. Journal of the American College of Cardiology, 82(9), 833–955. https://doi.org/10.1016/j.jacc.2023.06.006

American Diabetes Association Professional Practice Committee. (2024). 10. Cardiovascular disease and risk management: Standards of care in diabetes—2024. Diabetes Care, 47(Suppl. 1), S179–S218. https://doi.org/10.2337/dc24-S010

Pinkosky, S. L., Newton, R. S., Day, E. A., Ford, R. J., Lhoták, Š., Austin, R. C., Birch, C. M., Smith, B. K., Filippov, S., Groot, P. H. E., Steinberg, G. R., & Lalwani, N. D. (2016). Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis. Nature Communications, 7, 13457. https://doi.org/10.1038/ncomms13457

Abdul-Rahman, T., Bukhari, S. M. A., Herrera, E. C., Awuah, W. A., Lawrence, J., de Andrade, H., Patel, N., Shah, R., Shaikh, R., Capriles, C. A. A., Ulusan, S., Ahmad, S., Corriero, A. C., Mares, A. C., Goel, A., Hajra, A., Bandyopadhyay, D., & Gupta, R. (2022). Lipid lowering therapy: An era beyond statins. Current Problems in Cardiology, 47(12), 101342. https://doi.org/10.1016/j.cpcardiol.2022.101342

National Institute of Diabetes and Digestive and Kidney Diseases. (2023). Bempedoic acid. In LiverTox: Clinical and research information on drug-induced liver injury. https://www.ncbi.nlm.nih.gov/books/NBK594232/

Oliver, W., & Giugliano, R. P. (2023). Benefit of combination ezetimibe/simvastatin among high-risk populations: Lessons from the IMPROVE-IT trial. Current Atherosclerosis Reports, 25(3), 85–93. https://doi.org/10.1007/s11883-023-01071-5

Ballantyne, C. M., Banach, M., Mancini, G. B. J., Lepor, N. E., Hanselman, J. C., Zhao, X., & Leiter, L. A. (2018). Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study. Atherosclerosis, 277, 195–203. https://doi.org/10.1016/j.atherosclerosis.2018.06.002

Toth, P. P., Bray, S., Villa, G., Palagashvili, T., Sattar, N., Stroes, E. S. G., & Worth, G. M. (2022). Network meta-analysis of randomized trials evaluating the comparative efficacy of lipid-lowering therapies added to maximally tolerated statins for the reduction of low-density lipoprotein cholesterol. Journal of the American Heart Association, 11(18), e025551. https://doi.org/10.1161/JAHA.122.025551

Seijas-Amigo, J., Cordero, A., Olmo, R. F., Cortez Quiroga, G. A., Fácila, L., Salgado-Barreira, Á., Reyes-Santías, F., Romero-Menor, C., Murillo, J. R., Rodríguez-Mañero, M., Bello Mora, M. C., Valle, A., Sandín, M., Pamias, R. F., Bañeras, J., García, P. B., Lorenzo, M. C., Sánchez-Alvarez, S., López-Rodríguez, L., & González-Juanatey, J. R. (2023). Patients with high cardiovascular risk as candidates to bempedoic acid after treatment with statins, ezetimibe and PCSK9 inhibitors: An estimation and cost-effectiveness analysis. Journal of Cardiovascular Pharmacology, 81(1), 70–75. https://doi.org/10.1097/FJC.0000000000001348

Amore, B. M., Sasiela, W. J., Ries, D. K., Tresh, P., & Emery, M. G. (2022). Pharmacokinetics of bempedoic acid in patients with renal impairment. Clinical and Translational Science, 15(3), 789–798. https://doi.org/10.1111/cts.13191

Ballantyne, C. M., Bays, H., Catapano, A. L., Goldberg, A., Ray, K. K., & Saseen, J. J. (2021). Correction to: Role of bempedoic acid in clinical practice. Cardiovascular Drugs and Therapy, 35(4), 865. https://doi.org/10.1007/s10557-021-07192-0

Jadhav, S. B., Crass, R. L., Chapel, S., Kerschnitzki, M., Sasiela, W. J., Emery, M. G., Amore, B. M., Barrett, P. H. R., Watts, G. F., & Catapano, A. L. (2022). Pharmacodynamic effect of bempedoic acid and statin combinations: Predictions from a dose-response model. European Heart Journal–Cardiovascular Pharmacotherapy, 8(6), 578–586. https://doi.org/10.1093/ehjcvp/pvac018


Refbacks

  • There are currently no refbacks.